Table 1.
Baseline Characteristics and Metabolic Parameters Among Fasted Subjects
| Characteristic | Total (N = 1797) | Treatment |
||
|---|---|---|---|---|
| ATV/r (n = 602) | RAL (n = 600) | DRV/r (n = 595) | ||
| Female sex | 432 (24) | 143 (24) | 146 (24) | 143 (24) |
| Age, y, mean (SD) | 37.37 (11.02) | 37.60 (10.84) | 37.00 (10.81) | 37.52 (11.40) |
| Race/ethnicity | ||||
| White non-Hispanic | 612 (34) | 212 (35) | 212 (35) | 188 (32) |
| Black non-Hispanic | 753 (42) | 250 (42) | 253 (42) | 250 (42) |
| Hispanic (regardless of race) | 385 (21) | 124 (21) | 115 (19) | 146 (25) |
| Other | 43 (2) | 15 (2) | 18 (3) | 10 (2) |
| Weight, kg, mean (SD) | 78.64 (18.36) | 78.97 (18.92) | 78.84 (18.49) | 78.11 (17.66) |
| BMI, kg/m2, mean (SD) | 26.14 (5.93) | 26.22 (6.10) | 26.26 (5.85) | 25.94 (5.82) |
| Baseline HIV-1 RNA, log10 copies/mL, mean (SD) | 4.63 (0.72) | 4.63 (0.73) | 4.65 (0.71) | 4.60 (0.71) |
| Baseline CD4+ count, cells/µL, mean (SD) | 308.45 (192.27) | 309.16 (188.96) | 306.07 (198.59) | 310.15 (189.38) |
| Fasting TC, mg/dL | ||||
| Median (Q1, Q3) | 154 (133, 178) | 154 (134, 176) | 155 (134, 181) | 154 (133, 179) |
| <200 mg/dL | 1,589 (88) | 537 (89) | 523 (87) | 529 (89) |
| Fasting HDL-C, mg/dL | ||||
| Median (Q1, Q3) | 38 (31, 46) | 37 (30, 45) | 38 (31, 46) | 38 (31, 47) |
| >40 mg/dL | 780 (43) | 249 (41) | 272 (45) | 259 (44) |
| Fasting TG, mg/dL | ||||
| Median (Q1, Q3) | 103 (73, 148) | 105 (74, 150) | 103 (73, 146) | 99 (73, 148) |
| <150 mg/dL | 1,352 (75) | 449 (75) | 456 (76) | 447 (75) |
| Fasting non-HDL-C, mg/dL | ||||
| Median (Q1, Q3) | 114 (95, 138) | 115 (96, 137) | 115 (96, 140) | 112 (93, 138) |
| <160 mg/dL | 1,606 (89) | 542 (90) | 533 (89) | 531 (89) |
| Fasting calculated LDL-C, mg/dLa | ||||
| Median (Q1, Q3) | 92 (74, 112) | 93 (75, 111) | 93 (74, 115) | 89 (73, 111) |
| <130 mg/dL | 1,606 (89) | 542 (90) | 528 (88) | 536 (90) |
| Fasting glucose, mg/dL | ||||
| Median (Q1, Q3) | 84 (78, 92) | 85 (79, 93) | 85 (78, 92) | 83 (77, 91) |
| <100 mg/dL | 1602 (89) | 529 (88) | 539 (90) | 534 (90) |
| Presence of metabolic syndrome | 381 (21) | 141 (23) | 121 (20) | 119 (20) |
| Smoking status | ||||
| History of smoking | 1,044 (58) | 358 (59) | 349 (58) | 337 (57) |
| Smoking history >10 y | 678 (38) | 249 (41) | 225 (38) | 204 (34) |
| Current smoker | 706 (39) | 251 (42) | 241 (40) | 214 (36) |
| On lipid-lowering treatment | 106 (6) | 33 (5) | 35 (6) | 38 (6) |
| On antihypertensive agents | 273 (15) | 95 (16) | 89 (15) | 89 (15) |
| Hypoglycemic agents | 64 (4) | 24 (4) | 21 (3) | 19 (3) |
Data are presented as No. (%) unless otherwise specified.
Abbreviations: ATV/r, ritonavir-boosted atazanavir; BMI, body mass index; DRV/r, ritonavir-boosted darunavir; HDL-C, high-density liproprotein cholesterol; HIV-1, human immunodeficiency virus type 1; LDL, low-density liproprotein cholesterol; RAL, raltegravir; SD, standard deviation; TC, total cholesterol; TG, triglycerides.
a Calculated as [fasting calculated LDL-C (mg/dL) = fasting TC – fasting HDL-C – (fasting TG/5)], only for subjects with fasting TG ≤400 mg/dL; subjects with fasting TG >400 mg/dL were excluded.